

## Metabolic Syndrome and Restrictive Ventilatory Defect

### Title:

The gender gap in the relationship between Metabolic Syndrome and Restrictive Ventilatory Defect

Running title: Metabolic Syndrome and Restrictive Ventilatory Defect

### Authors:

Ya-Chun Chu<sup>a,b</sup>; Chi-Chiang Yang<sup>b,c</sup>; Shaw-Ji Chen<sup>b,d,e</sup>; Pei-Ling Cheng<sup>a</sup>; Mei-Chuan Wu<sup>a</sup>; Hsin-Hung Wu<sup>f\*</sup>; Jerry Cheng-Yen Lai<sup>b\*</sup>

### Affiliations:

<sup>a</sup> Department of Respiratory Therapy Center, Taitung MacKay Memorial Hospital, Taitung, Taiwan. Address: No.1, Lane 303, Changsha Street, Taitung City 95054, Taiwan.

<sup>b</sup> Master Program in Biomedicine, National Taitung University, Taitung, Taiwan. Address: No.684, Sec. 1, Zhonghua Rd, Taitung City 95002, Taiwan.

<sup>c</sup> Biomedicine, Agriculture, and Food Science Research Center, National Taitung University, Taitung, Taiwan. Address: No.684, Sec. 1, Zhonghua Rd, Taitung City 95002, Taiwan.

<sup>d</sup> Department of Psychiatry, Taitung MacKay Memorial Hospital, Taitung, Taiwan. Address: No.1, Lane 303, Changsha Street, Taitung City 95054, Taiwan.

<sup>e</sup> Department of Medicine, MacKay Medical College, New Taipei, Taiwan. Address: No. 46, Section 3, Zhongzheng Rd, Sanzhi District, New Taipei City 25245, Taiwan.

<sup>f</sup> Department of Pulmonary Medicine, Taitung MacKay Memorial Hospital, Taitung, Taiwan. Address: No.1, Lane 303, Changsha Street, Taitung City 95054, Taiwan.

### \*Corresponding Authors:

#### \*Hsin-Hung Wu, MD

Email: [a5809@mmh.org.tw](mailto:a5809@mmh.org.tw) (HH Wu)

ORCID: 0009-0006-0074-0190

#### \*Jerry Cheng-Yen Lai, PhD

E-mail: [chengyen@hotmail.com](mailto:chengyen@hotmail.com) (JC Lai)

ORCID: 0000-0001-8280-144X

## Metabolic Syndrome and Restrictive Ventilatory Defect

### Author Contributions

**Conceptualization:** Ya-Chun Chu; Chi-Chiang Yang; Hsin-Hung Wu; Jerry Cheng-Yen Lai.

**Data curation:** Ya-Chun Chu; Shaw-Ji Chen; Jerry Cheng-Yen Lai.

**Formal analysis:** Ya-Chun Chu; Chi-Chiang Yang; Shaw-Ji Chen; Jerry Cheng-Yen Lai.

**Funding acquisition:** Jerry Cheng-Yen Lai; Pei-Ling Cheng; Mei-Chuan Wu.

**Investigation:** Ya-Chun Chu; Pei-Ling Cheng.

**Methodology:** Ya-Chun Chu; Shaw-Ji Chen; Hsin-Hung Wu; Jerry Cheng-Yen Lai.

**Project administration:** Chi-Chiang Yang; Pei-Ling Cheng; Hsin-Hung Wu.

**Resources:** Chi-Chiang Yang; Pei-Ling Cheng; Mei-Chuan Wu.

**Software:** Pei-Ling Cheng; Jerry Cheng-Yen Lai.

**Supervision:** Shaw-Ji Chen; Mei-Chuan Wu; Hsin-Hung Wu; Jerry Cheng-Yen Lai.

**Validation:** Ya-Chun Chu; Hsin-Hung Wu; Jerry Cheng-Yen Lai.

**Visualization:** Ya-Chun Chu; Chi-Chiang Yang; Hsin-Hung Wu.

**Writing - original draft:** Ya-Chun Chu; Chi-Chiang Yang; Shaw-Ji Chen; Jerry Cheng-Yen Lai.

**Writing - review&editing:** Ya-Chun Chu; Hsin-Hung Wu; Jerry Cheng-Yen Lai.

### Review of manuscript

All authors read and approved the final manuscript.

### Funding Sources

This study was supported by grants TTMMH-107-07 and TTMMH-111-08 from Taitung MacKay Memorial Hospital, Taitung, Taiwan. The funding sources were not involved in the study or article preparation.

### Conflict of Interest

The authors declared no conflict of interest.

### Financial Conflict

none declared.

### Data availability statement

The data that support the findings of this study are available from the Taiwan Biobank but restrictions apply to the availability of these data, which were used under license for this study. Data are however available from the authors upon reasonable request with the permission of Taiwan Biobank.

## Abstract

**Background:** Given the fundamental physiological differences between the sexes, this study aimed to investigate the effect of metabolic syndrome on ventilatory defects stratified by sex.

**Methods:** We conducted a nationwide, pooled, cross-sectional study. Data of 45,788 participants (men, n=15,859; women, n=29,929) aged 30 years or more were obtained from the Taiwan Biobank. Age-sex adjusted and multivariate logistic regression models were used to estimate the risk of developing impaired pulmonary function (restrictive or obstructive ventilatory defect) in individuals with or without metabolic syndromes. Separate models were also used to estimate for the risk of metabolic syndrome scores and the risk of individual metabolic abnormalities on the risk of restrictive ventilatory defect.

**Results:** The overall prevalence of metabolic syndrome was estimated to be 15.9% in Taiwan, much higher in men than in women (18.6% versus 14.4%). Significant association was observed on the effect of metabolic syndromes on the risk of restrictive ventilatory defect. The risk of developing restrictive ventilator defect was 35% higher in participants with metabolic syndromes (odds ratio, 1.35; 95% confidence interval, 1.26-1.45) than those without metabolic syndromes. Elevated blood pressure and triglycerides abnormality were important predictors of restrictive ventilator defect.

Sex-stratified subgroup analyses of the individual metabolic abnormalities indicated that men with abdominal obesity and women with dysglycemia were more likely to develop restrictive ventilatory defect.

**Conclusion:** Our study evidences suggested that metabolic syndromes were important predictors of impaired pulmonary function and increased risk of developing restrictive ventilatory defects, and its risk increased with increasing numbers of metabolic abnormalities.

**Keywords:** abdominal obesity, dysglycemia, gender gap, lung function, metabolic syndrome

## Metabolic Syndrome and Restrictive Ventilatory Defect

### 1 **Introduction**

2           Metabolic syndrome (MetS) is a condition that includes a cluster of risk metabolic  
3 abnormalities for a variety of diseases, including abdominal obesity (increasing waist circumference  
4 [WC]), high blood pressure (BP), high level of fasting plasma glucose (FPG), high level of  
5 triglyceride (TG), and low level of high-density lipoprotein cholesterol (HDL-C) levels. The MetS  
6 prevalence rates differed considerably from as high as 39.4%-57.1% in several Western countries  
7 (Finland, Italy, Mexico) to as low as 3.2%-15.5% (Poland, China, Turkey) [1]. In contrast, MetS is  
8 one of the most rapidly increasing chronic conditions in the Taiwanese population. According to the  
9 Nutrition and Health Survey in Taiwan, the prevalence rate of MetS has nearly tripled from 11.9%  
10 in 1993 to 34.6% in 2020 in the adult population [2]. An important sequel is the increased risk of  
11 cardiovascular disease, diabetes, hypertension, and hyperlipidemia in people with MetS, which is 2  
12 to 6 times higher than in normal people [3]. Inadequate pulmonary ventilation would irritate the  
13 medulla oblongata to compensate by rising respiratory rates. This situation may lower exercise  
14 tolerance or cause shortness of breath and orthopnea. Compensation failure would contribute to  
15 chronic hypoxia or muscle atrophy, and long-term respiratory failure could lead to changes in lung  
16 structure, increasing the risk of pulmonary hypertension and Cor Pulmonale [4]. Given the  
17 fundamental physiological differences between the sexes, women used more movement of the chest  
18 and ribs than men during deep breathing, while men mainly applied the diaphragm expansion and  
19 abdominal muscles to breathe [5]. The Korean National Health and Nutrition Examination Survey  
20 reported that WC, BP, FPG, and HDL-C independently related to forced vital capacity of predicted

## Metabolic Syndrome and Restrictive Ventilatory Defect

21 % (FVC % of predicted) in men while waist circumference significantly correlated with FVC  
22 predicted (%) in women [6]. In contrast, in a study of 6,945 Taiwanese participants, a negative  
23 correlation was reported between WC and FVC % predicted in men younger than 45 years, while  
24 no correlation between metabolic abnormality and FVC % predicted was observed in women [7].

25       Despite many published studies on the association between MetS and impaired pulmonary  
26 function, no consistent evidences are available in the literature by sex. We aimed to compare the  
27 risk of developing impaired pulmonary function between individuals with or without MetS for each  
28 gender using a nationwide, pooled, cross-sectional study design in Taiwan. We hypothesized that  
29 sex was an independent predictor of impaired pulmonary functions, and the effects of MetS on  
30 impaired pulmonary functions differed by sex among community-dwelling adult population in  
31 Taiwan.

## 32 **Methods**

### 33 **1. Study design and data source**

34 We conducted a nationwide, pooled, cross-sectional study using the data obtained from the  
35 Taiwan Biobank. Taiwan Biobank is a largescale biomedical research database that intends to  
36 recruit 200,000 community-dwelling healthy volunteers aged 30-79 years residing in Taiwan that  
37 consists of genetic and medical information as on predominantly Han Chinese-ancestry individuals  
38 [8]. All participants in the Taiwan Biobank provided written informed consent before data  
39 collection. The vertical data integration of the collected samples provide data accessible to the  
40 community dwelling population in Taiwan. As stipulated by the Human Biobank Management Act,  
41 the data of all participants were de-identified with uniquely encrypted identification numbers in the  
42 Taiwan Biobank. As a reliable data source, studies using this database have been published in top-  
43 tier journals [9, 10]. This study has been reviewed and approved by the Human Research Ethics  
44 Review Committee of the MacKay Memorial Hospital (21MMHIS351e).

### 45 **2. Study population**

46 Using data released in 2021, a total of 132,720 adult participants recruited between 2008 and  
47 2020 were available for analyses. The exclusion criteria were: (1) participants with missing  
48 information on pulmonary function (n=50,310) and metabolic abnormalities (n=47); (2) to ensure  
49 the precision of the blood glucose and lipids test results, blood sugar test results with less than 8  
50 hours of fasting were excluded (n=21,854); (3) to maintain homogeneity in prognosis, we excluded  
51 all participants with cancers, respiratory diseases, cardiovascular diseases, and metabolic-related

## Metabolic Syndrome and Restrictive Ventilatory Defect

52 diseases (n=13,011), and covariates due to incomplete data (n=1,710). A total of 45,788 participants  
53 aged 30 years or more were included in the final analysis.

### 54 **3. Analysis of covariates**

55 Participants' residential urbanicity was defined according to Liu et al [11]. Education levels  
56 were divided into college and above (university and graduate school or above), middle school  
57 education (junior high and senior high school) and elementary school (elementary school or  
58 illiterate). Participants were classified into never smoking, former smoking (did not smoke in recent  
59 six months), or current smoking (for more than six months). The habit of drinking was defined as  
60 150cc per week for 6 months, and former drinking was defined as not drinking for more than 6  
61 months. Monthly exercise habits classified the participants using the metabolic equivalent for task  
62 (MET) as never or seldom physical activity, doing light physical activity (monthly physical exercise  
63 <1800 MET), moderate physical activity (monthly physical exercise=1800-3600 MET), or vigorous  
64 physical activity (monthly physical exercise > 3600 MET) [12]. MET is a unit that estimates the  
65 amount of energy (kcal/kg/hour) used by an individual during physical activity, and the values were  
66 multiplied by 150 minutes as suggested by the World Health Organization [13].

### 67 **4. Definition of metabolic abnormalities**

68 According to the modified National Cholesterol Education Program Adult Treatment Panel III  
69 (NCEP ATP III), individuals having at least three of the five metabolic abnormalities were  
70 diagnosed as having MetS [14]: 1) abdominal obesity: WC  $\geq$ 90 cm in men and  $\geq$ 80 cm in women;  
71 2) hypertriglyceridemia: TGs  $\geq$  150 mg/dL or pharmacotherapy for hyperlipidemia ; 3) reduced

## Metabolic Syndrome and Restrictive Ventilatory Defect

72 HDL-C level: HDL-C < 40 mg/dL in men and < 50 mg/dL in women; 4) elevated BP: systolic  
73 blood pressure  $\geq 130$ mmHg or diastolic blood pressure  $\geq 85$  mmHg or pharmacotherapy for  
74 hypertension; 5) elevated FPG  $\geq 100$  mg/dL or pharmacotherapy for glucose-lowering medication.

### 75 **5. Pulmonary function testing**

76 The pulmonary function was performed by Lilly-type pneumotach sensor spirometer (HI-801,  
77 CHEST M.I., INC, Tokyo, Japan) with specially trained technicians according to the American  
78 Thoracic Society recommendations. All spirometric parameters were repeated for three or more  
79 times with similar results to meet the criteria for acceptability and reproducibility. The spirometric  
80 parameters were compared with the estimated values of the prediction lung function formula  
81 adjusting for race, sex, age, and height, which were used to calculate FEV1 (forced expiratory  
82 volume in one second) predicted %, FVC (forced vital capacity) predicted % and FEV1 to FVC  
83 ratio. Respiratory dysfunction can be classified into obstructive ventilatory defect (OVD) and  
84 restrictive ventilatory defect (RVD). The pulmonary function test results were classified as normal  
85 ventilatory function (FEV1/FVC  $\geq 70\%$ ), RVD (FEV1/FVC  $\geq 70\%$  & FVC < 80% of predicted), and  
86 OVD (FEV1/FVC < 70%) [15-18].

### 87 **6. Statistical analysis**

88 Chi-squared test for categorical variables and Student's t-test for continuous variables were used  
89 to compare group differences. Age-sex adjusted and multivariate logistic regression models were  
90 used to estimate the risk of developing impaired pulmonary function (RVD or OVD) between  
91 individuals with or without MetS stratified by sex and age. Separate models were also used to



## Metabolic Syndrome and Restrictive Ventilatory Defect

92 estimate for the risks of metabolic syndrome scores (MSS) and individual metabolic abnormalities  
93 on the risk of RVD. The reported P values were based on a two-tailed test, and  $P < 0.05$  indicated a  
94 statistically significant. All data conversions and analyses were performed using SAS for Windows  
95 release 9.4 (SAS Institute Inc, Cary, NC).

## 96 **Results**

### 97 **1. Baseline characteristics**

98 Table 1 compares basic demographic characteristic (age, obese status, residential urbanicity,  
99 and education level), healthy lifestyle behaviors, family medical history, metabolic abnormalities,  
100 and information related to pulmonary impairment between sexes. Most participants were women  
101 (65.4%) aged 30-59 years, resided in urbanized community, and attended college or graduate  
102 school. In general, men had a significantly higher incidences of metabolic abnormalities than  
103 women, including elevated FPG (29.3% vs 17.2%), TGs (28.8% vs 15.2%), and BP (36.8% vs  
104 20.7%). On the contrary, women had higher incidences of abdominal obesity (28.3% vs 19.3%) and  
105 high-density cholesterol (26.8% vs 21.6%).

### 106 **2. Effects of MetS on pulmonary function and ventilatory defect**

107 The overall prevalence rate of MetS was estimated to be 15.9% in Taiwan, much higher in men  
108 than in women (18.6% versus 14.4%) (Table 1). Of these, 16.7% had RVDs and 13.6% had OVDs.  
109 Although higher proportion of male participants had MetS (18.6% vs 14.4%) and unhealthy  
110 lifestyle behaviors (current smoking, 22.0% vs 2.9%; current drinking, 13.1% vs 1.9%) than female  
111 participants in this study, rates of impaired pulmonary function were markedly higher among  
112 women for both types of ventilatory defects (RVD, 18.7% vs 13.0%; OVD, 14.3% vs 12.3%). In  
113 both sex strata, MetS increased risk of developing impaired pulmonary function FVC<80% (Odds  
114 Ratio [OR], 1.33-1.34), similar in magnitude to that of all participants (OR, 1.34), which suggested  
115 that the outcome was independent of sex. Similarly, the risks of MetS on developing impaired

## Metabolic Syndrome and Restrictive Ventilatory Defect

116 function FEV1<80%, predicted (OR, 1.19-1.23 vs 1.22) (Table 2) and RVD (OR, 1.31-1.36 vs 1.35)  
117 (Table 3) were both independent of sex. On the contrary, MetS did not increase the risk of  
118 developing OVD after covariate adjustment (Table 3). Table 4 shows subgroup analysis stratified  
119 by the MSS scores for the presence of metabolic abnormalities from none (MSS=0) to 5 (MSS=5).  
120 In general, both men and women were associated with increased risk of developing RVD from for  
121 MSS stratification of 2 to 5. Once again, the magnitude of risk for each MSS stratum for each sex  
122 was similar to that of all participant, which suggested that the risk of RVD was independent of sex.  
123 Table 5 compares the effects of individual metabolic abnormalities on the risk of RVD by age and  
124 sex categories. In general, both men and women with elevated BP (OR, 1.27-1.46 vs 1.33) and TGs  
125 (1.19 - 1.35 vs 1.22) abnormalities were more likely to develop RVD and the risks were  
126 independent of both sex and age strata. Conversely, sex-stratified subgroup analyses of the  
127 individual metabolic abnormalities indicated that only women with elevated FPG (OR, 1.14-1.38 vs  
128 1.12) and men with abdominal obesity (OR, 1.24-1.30 vs 1.07) were more likely to develop RVD.  
129 Although the risk of RVD was associated with reduced HDL-C by sex (OR, 1.10-1.14) and for all  
130 participants (OR, 1.11), the risks of RVD were not statistically difference between age strata for  
131 men and only statically significance in women younger than 55 years (OR, 1.13).

## 132 **Discussion**

133 Our study evidence suggested that men and women aged 30 years or older with MetS were  
134 more likely to suffer from impaired pulmonary function and increased risk of developing RVD, and  
135 its risk increased with increasing numbers of metabolic abnormalities. Despite much higher  
136 prevalence of MetS and unhealthy lifestyle (smoking and drinking) behaviors in men than women,  
137 similar rates of increased risk of developing RVD (31%-36%) were found in both sexes, whereas  
138 the difference in the risk of OVD was not significant after adjusting for baseline demographic and  
139 lifestyle behaviors. Additionally, elevated BPs and TGs were both important predictors of RVD. In  
140 contrast, only men with abdominal obesity (or increasing WC) and women with dysglycemia  
141 (elevating fasting blood glucose) were more likely to develop RVD. Many studies demonstrated  
142 that the risk of developing RVD was associated with MetS [7, 19-24]. We observed an increased  
143 risk of RVD with increasing numbers of metabolic abnormalities, which was consistent with those  
144 reported by other researchers [7], [19, 25]. However, the results are not consistent in terms of the  
145 correlation between MetS and OVD [26]. Lam et al. classified patients of COPD from I to IV  
146 according to GOLD criteria, and found only a significant correlation between MetS and the worst  
147 COPD groups [27], which came up with similar results in a study on Japanese men [28]. In another  
148 study, Lee et al. study observed that diabetes is positively associated with RVD (OR:2.025, 95%  
149 CI:1.264-3.244), but no correlative with OVD (OR:0.982, 95%CI:0.634-1.519). They also found  
150 that subjects with RVD had the highest hs-CRP than other respiratory dysfunction [29].

151 Abdominal obesity is recognized as a major predicting factor for impaired respiratory function,

## Metabolic Syndrome and Restrictive Ventilatory Defect

152 which has been confirmed in many studies [25, 30]. Wang et al. found that abdominal obesity  
153 lowers FVC and FEV1 values but it did not affect the FEV1/FVC value [25]. Our study shows that  
154 men's WC over 90 cm would decrease ventilatory function, such as FVC<80% predicted and  
155 FEV1<80% predicted. In contrast, in a study of 6,945 Taiwanese participants, a negative correlation  
156 was reported between waist circumference and FVC % predicted in men younger than 45 years  
157 while no correlation between metabolic abnormality and FVC % predicted was observed in women  
158 [7]. On the other hand, the Korean National Health and Nutrition Examination Survey in 2007  
159 observed that WC, BP, FPG, and HDL-C independently related to FVC % of predicted in men  
160 while WC significantly correlated with FVC predicted (%) in women [6]. Obese men present as the  
161 deposit of fat in the chest, abdomen, and visceral organs, known as central obesity. In women, fat is  
162 usually stored in the buttocks, thighs, hips, and subcutaneous tissue, known as peripheral obesity  
163 [31]. Accumulated fat in the mediastinum and abdomen decreases the compliance of the chest wall,  
164 causing breathing pattern changes. Intra-abdominal pressure and intrapleural pressure would  
165 slightly increase in the obese which decreases differential pressure from the atmosphere to the chest  
166 leading to a ventilatory flow limit. In addition, the downward movement of the diaphragm and  
167 expansion of the chest would be restricted by adipose tissue in the abdomen, decreasing expiratory  
168 reserved volume and functional residual capacity making work of breath increasing and ventilatory  
169 efficiency lowering [15, 31]. However, it is still unclear whether obesity lower the compliance of  
170 lung, chest, or both [32]. Further studies are needed to confirm the association.

171 MetS is a chronic inflammatory state that would trigger immune response and proliferate

## Metabolic Syndrome and Restrictive Ventilatory Defect

172 inflammatory substances to reduce the pulmonary function. In our study, we found that men with  
173 abdominal obesity (or increasing WC) and women having dysglycemia (elevating FPG) had a  
174 higher risk of respiratory function (RVD) than those without these metabolic abnormalities. This  
175 indicated a sex-specific association between abnormal fasting blood glucose and the secretion of  
176 inflammatory substances. Kawamoto et al. reported a significant sex-specific correlation between  
177 fasting blood glucose and hsCRP, and women had a large increasing amplitude than men [33].  
178 Elevating hs-CRP amplitude different explained that women with high blood glucose will have a  
179 higher risk of cardiovascular disease than men in the future [34]. Likewise, Adipocyte accumulation  
180 due to obesity will secrete adipocytokines, such as Interleukin-6, TNF- $\alpha$ , interferon- $\gamma$ , and leptin,  
181 and stimulate the bronchial smooth muscle contraction and induce macrophages to move into the  
182 alveoli provoking chronic inflammation damage alveoli and airway, and increase respiratory  
183 symptoms [35].

184 There are some limitations to be considered while interpreting our study results. First, the  
185 measurement of the respiratory function with spirometry, rather than using the more bulky and  
186 expensive equipment such as body plethysmography, did not provide data on total lung capacity  
187 and residual volume, which could have resulted in residual confounding. Nevertheless, the use of  
188 spirometry with properly trained technicians is sufficient for early screening of respiratory function  
189 in the community. Second, respiratory symptoms that may be associated with ventilatory defect,  
190 such as cough and dyspnea, were not available in the Taiwan Biobank. We were therefore unable to  
191 assess the relationship between MetS and respiratory symptoms. Finally, the lack of data on

## Metabolic Syndrome and Restrictive Ventilatory Defect

- 192 inflammatory substances such as hs-CPR prevent further investigation on the association between
- 193 inflammatory substances and impaired respiratory function.

194 **Conclusion**

195       Despite limitation, our study evidences suggested that metabolic syndromes were important  
196 predictors of impaired pulmonary function and increased risk of developing restrictive ventilatory  
197 defects, and its risk increased with increasing numbers of metabolic abnormalities. If gender-  
198 specific prevention strategies can be tailored for individuals at increased risk of impairment  
199 pulmonary function, further studies are required to determine the metabolic effects of medications  
200 as well as modifiable lifestyle behaviors on metabolic abnormalities



Metabolic Syndrome and Restrictive Ventilatory Defect

	Men	Women	P-value
<b>Independent Variables</b>			
Participants, n (%)	15,859 (34.6)	29,929 (65.4)	<.001
Age, mean (SD), y	48.8(11.3)	49.3(10.6)	<.001
Age, n (%)			
30-39 y	4,198 (26.5)	6,893 (23.0)	<.001
40-49 y	4,053 (25.6)	7,618 (25.5)	
50-59 y	4,123 (26.0)	9,513 (31.8)	
60-69 y	3,396 (21.4)	5,828 (19.5)	
≥70 y	89 (0.6)	77 (0.3)	
Residential urbanicity, n (%)			
Urban	9,329(58.8)	18,002(60.2)	.017
Suburban	5,695(35.9)	10,450(34.9)	
Rural	835(5.3)	1,477(4.9)	
Education level, n (%)			
College or graduate School	10,840 (68.4)	16,443 (54.9)	<.001
High school	4,658 (29.4)	11,842 (39.6)	
No or elementary school	361 (2.3)	1,644 (5.5)	
Smoking experience, n (%)			
Never smoke	8,797 (55.5)	28,305 (94.6)	<.001
Former smoke	3,563 (22.5)	747 (2.5)	
Current smoke	3,499 (22.1)	877 (2.9)	
Drinking habits, n (%)			
Never drink	13,005 (82.0)	29,132 (97.3)	<.001
Former drink	774 (4.9)	235 (0.8)	
Current drink	2,080 (13.1)	562 (1.9)	
Monthly exercise habits, n (%)			
Never or seldom physical activity	9,428 (59.5)	18,266 (61.0)	<.001
Light physical activity	646 (4.1)	1,740 (5.8)	
Moderate physical activity	1,696 (10.7)	3,756 (12.6)	
Vigorous physical activity	4,089 (25.8)	6,167 (20.6)	
BMI, mean (SD)	25.2(3.5)	23.5(3.7)	<.001
Obese status (BMI ≥ 27), n(%)	4,109 (25.9)	4,549 (15.2)	<.001
Body fat rate, n (%)	22.9(5.3)	31.8(6.3)	<.001
Family medical history*			
Asthma	1,067(6.7)	2,541(8.5)	<.001
Emphysema or Chronic bronchitis	337(2.1)	828(2.8)	<.001
Cardiovascular disease	5,383(33.9)	11,262(37.6)	<.001
Diabetes	5,081(32.0)	11,109(37.1)	<.001
Metabolic syndrome, n (%)	2,955 (18.6)	4,304 (14.4)	<.001
Metabolic abnormalities, n (%)			
Fasting glucose ≥ 100 mg/dL	4,642 (29.3)	5,143 (17.2)	<.001

Metabolic Syndrome and Restrictive Ventilatory Defect			
TGs $\geq$ 150 mg/dL	4,559 (28.8)	4,647 (15.5)	<.001
HDL-C < 40 mg/dL in men or HDL-C < 50 mg/dL in women	3,421 (21.6)	8,005 (26.8)	<.001
SBP $\geq$ 130 mmHg or DBP $\geq$ 85 mmHg,	5,834 (36.8)	6,180 (20.7)	<.001
WC $\geq$ 90 cm in men or WC $\geq$ 80 cm in women	3,061 (19.3)	8,468 (28.3)	<.001
Lung function parameters			
FEV1, mean (SD), L	2.9 (0.8)	2.0 (0.6)	<.001
FVC, mean (SD), L	3.6 (0.7)	2.4 (0.5)	<.001
FEV1, % predicted	89.1 (22.0)	83.8 (22.5)	<.001
FVC, % predicted	94.2 (15.2)	91.0 (16.8)	<.001
FEV1 /FVC ratio	95.2 (20.8)	92.5 (20.7)	<.001
Lung function parameters, n (%)			
FEV1 < 80% predicted	4,084 (25.8)	10,667 (35.6)	<.001
FVC < 80% predicted	2,348 (14.8)	6,674 (22.3)	<.001
Lung function diagnosis, n (%)			
Normal ventilatory function	11,855 (74.8)	20,025 (66.9)	<.001
Restrictive ventilatory defect	2,058 (13.0)	5,610 (18.7)	
Obstructive ventilatory defect	1,946 (12.3)	4,294 (14.3)	

**Table 1.** Baseline characteristics of total participants stratified by sex (N=45,788).

SD, standard deviation; Mets, metabolic syndrome; WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TGs, triglycerides; HDL-C, High-density lipoprotein Cholesterol; FVC, Forced volume capacity; FEV1, Force expiratory volume in one second; *P*-value,  $\chi^2$  test or Student *t*-test.

\* Family medical history of the participant's second degree of blood relatives were included in the family medical history. Cardiovascular disease consisted of vascular heart disease, coronary heart disease, arrhythmia, cardiomyopathy, congenital heart disease, hyperlipidemia, hypertension, and stroke.

**Table 2.** The effects of metabolic syndrome on the risk of impaired pulmonary function by sex.

Independent Variables	FVC<80%, predicted			FEV1<80%, predicted				
	Age- sex-adjusted OR, (95% CI)		Multivariable-adjusted OR, (95% CI)		Age- sex-adjusted OR, (95% CI)	Multivariable-adjusted OR, (95% CI)		
All participants	1.20 (1.13-1.27) <sup>c</sup>	***	1.34 (1.25-1.44) <sup>d</sup>	***	1.05 (1.00-1.11) <sup>c</sup>	1.22 (1.15-1.30) <sup>d</sup>	***	
Men	1.37 (1.23-1.52) <sup>b</sup>	***	1.33 (1.18-1.50) <sup>a</sup>	***	1.18 (1.08-1.29) <sup>b</sup>	***	1.23 (1.11-1.36) <sup>a</sup>	***
Women	1.13 (1.05-1.22) <sup>b</sup>	**	1.34 (1.23-1.46) <sup>e</sup>	***	0.99 (0.92-1.06) <sup>b</sup>		1.19 (1.10-1.29) <sup>e</sup>	***

BMI, body mass index; OR, Odds ratio; CI, Confidence interval; FVC, Forced volume capacity; FEV1, Force expiratory volume in one second;  $P<0.05^*$ ,  $P<0.01^{**}$ ,  $P<0.001^{***}$  ( $P$ -value)

a. Odds ratio adjusted for age, smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

b. Odds ratio adjusted for only age.

c. Odds ratio adjusted for only sex and age.

d. Odds ratio adjusted for all variables in footnote a and sex.

e. Odds ratio adjusted for all variables in footnote a and menopausal status.

**Table 3.** The effects of metabolic syndrome on the risk of ventilatory defect with sex.

Independent Variables	Restrictive ventilatory defect			Obstructive ventilatory defect			
	Age- sex-adjusted OR, (95% CI)		Multivariable-adjusted OR, (95% CI)		Age- sex-adjusted OR, (95% CI)	Multivariable-adjusted OR, (95% CI)	
All participants	1.27 (1.19-1.35) <sup>c</sup>	***	1.35 (1.26-1.45) <sup>d</sup>	***	0.86 (0.79-0.93) <sup>c</sup>	***	0.97 (0.89-1.06) <sup>d</sup>
Men	1.44 (1.29-1.61) <sup>b</sup>	***	1.31 (1.16-1.49) <sup>a</sup>	***	0.92 (0.81-1.04) <sup>b</sup>		1.05 (0.91-1.21) <sup>a</sup>
Women	1.20 (1.11-1.30) <sup>b</sup>	***	1.36 (1.24-1.48) <sup>e</sup>	***	0.82 (0.74-0.91) <sup>b</sup>	**	0.92 (0.82-1.03) <sup>e</sup>

BMI, body mass index; OR, Odds ratio; CI, confidence interval; Restrictive ventilatory defect: FEV1/FVC  $\geq$  70% and FVC, predicted% < 80%; Obstructive ventilatory defect: FEV1/FVC < 70%;  $P < 0.05^*$ ,  $P < 0.01^{**}$ ,  $P < 0.001^{***}$  ( $P$ -value)

a. Odds ratio adjusted for age, smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

b. Odds ratio adjusted for only age.

c. Odds ratio adjusted for only sex and age.

d. Odds ratio adjusted for all variables in footnote a and sex.

e. Odds ratio adjusted for all variables in footnote a and menopausal status.

**Table 4.** The effects of metabolic syndrome scores on the risk of restrictive ventilatory defect by sex.

OR, (95% CI)	Non-metabolic syndrome			Metabolic syndrome		
	MSS=0	MSS=1	MSS=2	MSS=3	MSS=4	MSS=5
Multivariable-adjusted <sup>b</sup>	1	1.06 (0.99 -1.13)	1.21 (1.11 -1.31) ***	1.41 (1.28 -1.56) ***	1.51 (1.33 -1.72) ***	2.40 (1.94 -2.97) ***
Men <sup>a</sup>	1	1.15 (1.00 -1.32) *	1.34 (1.16 -1.56) ***	1.52 (1.27 -1.81) ***	1.58 (1.26 -1.99) ***	2.75 (1.87 -4.04) ***
Women <sup>c</sup>	1	1.04 (0.96 -1.13)	1.16 (1.06 -1.28) **	1.38 (1.23 -1.55) ***	1.49 (1.27 -1.74) ***	2.26 (1.75 -2.91) ***

BMI, body mass index; OR, Odds ratio; CI, confidence interval; MSS, metabolic syndrome score;  $P < 0.05^*$ ,  $P < 0.01^{**}$ ,  $P < 0.001^{***}$  ( $P$ -value)

a. Odds ratio adjusted for age, smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).

b. Odds ratio adjusted for all variables in footnote a and sex.

c. Odds ratio adjusted for all variables in footnote a and menopausal status.

Metabolic Syndrome and RVD

**Table 5.** The effects of each metabolic component on the risk of restrictive ventilatory defect by sex and age.

Independent Variables OR, (95% CI)	Whole population	Men	Women
Elevated BP <sup>f</sup>	1.33 (1.25-1.41) <sup>c</sup> ***	1.27 (1.14-1.40) <sup>b</sup> ***	1.36 (1.26-1.46) <sup>e</sup> ***
< 55 years old		1.31 (1.13-1.52) <sup>a</sup> ***	1.32 (1.16-1.49) <sup>d</sup> ***
>=55 years old		1.40 (1.22-1.61) <sup>a</sup> ***	1.46 (1.34-1.60) <sup>d</sup> ***
Elevated FPG <sup>g</sup>	1.12 (1.05-1.20) <sup>c</sup> ***	1.05 (0.94-1.16) <sup>b</sup>	1.15 (1.07-1.25) <sup>e</sup> ***
< 55 years old		1.07 (0.91-1.26) <sup>a</sup>	1.38 (1.21-1.57) <sup>d</sup> ***
>=55 years old		1.21 (1.05-1.39) <sup>a</sup> **	1.14 (1.04-1.26) <sup>d</sup> **
Reduced HDL-C <sup>h</sup>	1.11 (1.04-1.18) <sup>c</sup> ***	1.14 (1.02-1.28) <sup>b</sup> *	1.10 (1.03-1.18) <sup>e</sup> **
< 55 years old		1.15 (0.98-1.36) <sup>a</sup>	1.13 (1.02-1.24) <sup>d</sup> *
>=55 years old		1.13 (0.96-1.33) <sup>a</sup>	1.07 (0.97-1.18) <sup>d</sup>
Elevated TG <sup>i</sup>	1.22 (1.14-1.30) <sup>c</sup> ***	1.27 (1.15-1.42) <sup>b</sup> ***	1.19 (1.09-1.29) <sup>e</sup> ***
< 55 years old		1.35 (1.16-1.56) <sup>a</sup> ***	1.22 (1.07-1.38) <sup>d</sup> ***
>=55 years old		1.25 (1.07-1.46) <sup>a</sup> **	1.20 (1.08-1.34) <sup>d</sup> ***
Abdominal obesity <sup>j</sup>	1.07 (1.00-1.16) <sup>c</sup> *	1.26 (1.08-1.46) <sup>b</sup> **	1.03 (0.95-1.13) <sup>e</sup>
< 55 years old		1.30 (1.04-1.61) <sup>a</sup> *	1.09 (0.96-1.24) <sup>d</sup>
>=55 years old		1.24 (1.00-1.53) <sup>a</sup> *	1.00 (0.89-1.12) <sup>d</sup>

*P*<0.05\*, *P*<0.01\*\* , *P*<0.001\*\*\* (*P*-value)

- a. Odds ratio adjusted for smoking experience, drinking habits, monthly exercise habits, education level, residential urbanicity, BMI, body fat rate, family medical history (asthma, emphysema or chronic bronchitis, cardiovascular diseases, diabetes).
- b. Odds ratio adjusted for all variables in footnote a and age.
- c. Odds ratio adjusted for all variables in footnote a, sex and age.
- d. Odds ratio adjusted for all variables in footnote a and menopausal status.
- e. Odds ratio adjusted for all variables in footnote a, age and menopausal status.
- f. Elevated BP: Systolic blood pressure  $\geq 130$  mmHg or Diastolic blood pressure  $\geq 85$ mmHg.
- g. Elevated FPG: Fasting plasma glucose  $\geq 100$  mg/dL.
- h. Reduced HDL-C: High-density lipoprotein Cholesterol <40mg/dL in men or <50 mg/dL in women.
- i. Elevated TGs: Triglycerides  $\geq 150$  mg/dL.
- j. Abdominal obesity: Waist circumference  $\geq 90$  cm in men or  $\geq 80$  cm in women.

## References

- [1] Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. *Diabetol Metab Syndr* 2021; 13(1):25.
- [2] Wen-Harn P. Nutrition and Health Survey in Taiwan (NAHSIT) 2017-2022. *Health Promotion Administration in Taiwan*;2022:91-92
- [3] Tai TY. Metabolic syndrome prevention and control handbook. *Health Promotion Administration in Taiwan*;2007:67-118
- [4] Martinez-Pitre PJ, Sabbula BR, Cascella M. Restrictive Lung Disease. *StatPearls*: July 25, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK560880/> Accessed January 25 2023.
- [5] Kaneko H and Horie J. Breathing movements of the chest and abdominal wall in healthy subjects. *Respir Care* 2012; 57(9):1442-1451.
- [6] Choi J H, Park S, Shin YH, Kim MY, Lee Y J. Sex differences in the relationship between metabolic syndrome and pulmonary function: the 2007 Korean National Health and Nutrition Examination Survey. *Endocr J* 2011; 58(6):459-465.
- [7] Lee YY, Tsao YC, Yang CK, Chuang CH, Yu W, Chen J C, Li, WC. Association between risk factors of metabolic syndrome with lung function. *Eur J Clin Nutr* 2020; 74(5):811-817.
- [8] Feng YA, Chen CY, Chen TT, Kuo PH, Hsu YH, Yang HI, et al. Taiwan Biobank: A rich biomedical research database of the Taiwanese population. *Cell Genomics* 2022; 2(11):100197.
- [9] Lu MY, Cheng HY, Lai JC, Chen SJ. The Relationship between Habitual Coffee Drinking and the Prevalence of Metabolic Syndrome in Taiwanese Adults: Evidence from the Taiwan Biobank Database. *Nutrients* 2022; 14(9):1867.
- [10] Hsu CL, Huang WL, Chen HH, Cheng-Yen Lai J. Non-fermented tea consumption protects against osteoporosis among Chinese male elders using the Taiwan biobank database. *Sci Rep* 2022; 12(1):70-79.
- [11] CY Liu, YT Hung, YL Chuang, YJ Chen, WS Weng, JS Liu. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. *Journal of Health Management* 2006; 4(1):1-22.
- [12] Piercy K L.,Troiano R P.,Ballard R M.,Carlson S A.,Fulton J E.,Galuska D A, et al. The Physical Activity Guidelines for Americans. *Jama* 2018; 320(19):2020-2028.
- [13] Jetté M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. *Clin Cardiol* 1990; 13(8):555-565.
- [14] Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. *Atherosclerosis* 2006; 186(2):367-373.
- [15] Beachey W. *Respiratory Care Anatomy and Physiology: Foundations for Clinical Practice*, 2th edition. Elsevier Health Sciences; 2009:43-78.
- [16] Graham B L, Steenbruggen I, Miller MR, Barjaktarevic I Z, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and

## Metabolic Syndrome and RVD

- European Respiratory Society Technical Statement. *Am J Respir Crit Care Med* 2019; 200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.
- [17] Soriano JB, Miravittles M, García-Río F, Muñoz L, Sánchez G, Sobradillo V, et al. Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. *Prim Care Respir J* 2012; 21(2):187-193.
- [18] Pauwels R A, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001; 163(5):1256-1276.
- [19] Ford ES, Cunningham TJ, Mercado CI. Lung function and metabolic syndrome: Findings of National Health and Nutrition Examination Survey 2007–2010. *J Diabetes* 2014; 6(6):603-613.
- [20] Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. *Am J Respir Crit Care Med* 2009; 179(6):509-516.
- [21] Nakajima K, Kubouchi Y, Muneyuki T, Ebata M, Eguchi S, Munakata H. A possible association between suspected restrictive pattern as assessed by ordinary pulmonary function test and the metabolic syndrome. *Chest* 2008; 134(4):712-718.
- [22] Paek YJ, Jung KS, Hwang YI, Lee KS, Lee DR, Lee JU. Association between low pulmonary function and metabolic risk factors in Korean adults: the Korean National Health and Nutrition Survey. *Metabolism* 2010; 59(9):1300-1306.
- [23] Lin YC, Huang TJ, Yeh MH, Lin MS, Chen MY. Lung function impairment and cardiometabolic risks among rural adults: implication for an aging society. *BMC Public Health* 2021;21(1):960-969
- [24] Fimognari FL, Pasqualetti P, Moro L, Franco A, Piccirillo G, Pastorelli R, et al. The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. *J Gerontol A Biol Sci Med Sci* 2007; 62(7):760-765.
- [25] Wang F, Tian D, Zhao Y, Li J, Chen X, Zhang Y. High-Density Lipoprotein Cholesterol: A Component of the Metabolic Syndrome with a New Role in Lung Function. *Evid Based Complement Alternat Med* 2021; 2021:6615595.
- [26] Yoon H, Gi MY, Cha J A, Yoo CU, Park SM. The association between the metabolic syndrome and metabolic syndrome score and pulmonary function in non-smoking adults. *Diab Vasc Dis Res* 2018; 15(2):131-138.
- [27] Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. *Eur Respir J* 2010; 35(2):317-323.
- [28] Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. *Intern Med* 2010; 49(19):2093-2099.
- [29] Lee D Y and Nam SM. Association between restrictive pulmonary disease and type 2 diabetes in Koreans: A cross-sectional study. *World J Diabetes* 2020; 11(10):425-434.
- [30] Lin WY, Yao CA, Wang HC, Huang KC. Impaired lung function is associated with obesity and metabolic syndrome in adults. *Obesity* 2006; 14(9):1654-1661.



Metabolic Syndrome and RVD

- [31] Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. *J Appl Physiol* 2010; 108(1):206-211.
- [32] Barcelar Jde M, Aliverti A, Rattes C, Ximenes ME, Campos SL, Brandão DC, et al. The expansion of the pulmonary rib cage during breath stacking is influenced by age in obese women. *PLoS One* 2014; 9(11):e110959. doi: 10.1371/journal.pone.0110959.
- [33] Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. *Cardiovasc Diabetol* 2011; 10:51-58.
- [34] Ferrannini G, De Bacquer D, Vynckier P, De Backer G, Gyberg V, Kotseva K, et al. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. *Cardiovasc Diabetol* 2021; 20(1):38-49.
- [35] Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and Inflammation. *Curr Immunol Rev* 2008; 4(2):70-79.